










Candidate/ Program	Stage of Development			
	Research	Lead Optimization	IND Enabling	Phase I
TKM-HBV (RNAi)				
TKM-PLK1* (RNAi)				
OCB-030 (cyclophilin inhibitor)				
CYT003 (TLR9 agonist)				
cccDNA Formation Inhibitor				
Surface Antigen Secretion Inhibitor				
Core Protein/Capsid Assembly Inhibitors (2 Candidates)				
cccDNA Epigenetic Modifier				
STING Agonist				

**TKM-PLK1 is currently undergoing evaluation in Phase IIb clinical trials for oncology indications GI-NET/ACC and HCC.*